Your browser doesn't support javascript.
loading
Protein modification by short-chain fatty acid metabolites in sepsis: a comprehensive review.
Zhang, Liang; Shi, Xinhui; Qiu, Hongmei; Liu, Sijia; Yang, Ting; Li, Xiaoli; Liu, Xin.
Affiliation
  • Zhang L; Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing, China.
  • Shi X; Chongqing Key Laboratory of Drug Metabolism, Chongqing, China.
  • Qiu H; Key Laboratory for Biochemistry and Molecular Pharmacology of Chongqing, Chongqing, China.
  • Liu S; Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing, China.
  • Yang T; Chongqing Key Laboratory of Drug Metabolism, Chongqing, China.
  • Li X; Key Laboratory for Biochemistry and Molecular Pharmacology of Chongqing, Chongqing, China.
  • Liu X; Department of Pharmacology, College of Pharmacy, Chongqing Medical University, Chongqing, China.
Front Immunol ; 14: 1171834, 2023.
Article de En | MEDLINE | ID: mdl-37869005
Sepsis is a major life-threatening syndrome of organ dysfunction caused by a dysregulated host response due to infection. Dysregulated immunometabolism is fundamental to the onset of sepsis. Particularly, short-chain fatty acids (SCFAs) are gut microbes derived metabolites serving to drive the communication between gut microbes and the immune system, thereby exerting a profound influence on the pathophysiology of sepsis. Protein post-translational modifications (PTMs) have emerged as key players in shaping protein function, offering novel insights into the intricate connections between metabolism and phenotype regulation that characterize sepsis. Accumulating evidence from recent studies suggests that SCFAs can mediate various PTM-dependent mechanisms, modulating protein activity and influencing cellular signaling events in sepsis. This comprehensive review discusses the roles of SCFAs metabolism in sepsis associated inflammatory and immunosuppressive disorders while highlights recent advancements in SCFAs-mediated lysine acylation modifications, such as substrate supplement and enzyme regulation, which may provide new pharmacological targets for the treatment of sepsis.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Sepsie / Microbiome gastro-intestinal Limites: Humans Langue: En Journal: Front Immunol Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Suisse

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Sepsie / Microbiome gastro-intestinal Limites: Humans Langue: En Journal: Front Immunol Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Suisse